Sign In
Buy ASND
$216.79
+0.190 (+0.0877%)
At Close: Jun 03, 2026
Ascendant Announces New DPEM Survey to Investigate Mineralization at Depth and Provides Update on Its In-Fill Drill Program at Its Venda Nova Deposit at Lagoa Salgada
11:00am, Wednesday, 26'th Jan 2022 GlobeNewswire Inc.
TORONTO, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ascendant Resources Inc. (TSX: ASND, OTCQB: ASDRF) ("Ascendant" or the "Company”) is pleased to announce the commencement of an extensive Deep Penetratin
Ascendis Pharma AS (ASND) Surges 6.5%: Is This an Indication of Further Gains?
12:09pm, Tuesday, 25'th Jan 2022 Zacks Investment Research
Ascendis Pharma AS (ASND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price i
Ascendis Pharma AS (ASND) Surges 6.5%: Is This an Indication of Further Gains?
08:33am, Tuesday, 25'th Jan 2022
Ascendis Pharma AS (ASND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price i
Pfizer's (PFE), OPKO's BLA for Somatrogon Gets CRL From FDA
05:48pm, Monday, 24'th Jan 2022 Zacks Investment Research
The FDA issues a Complete Response Letter to Pfizer (PFE) and OPKO Health's biologics license application for somatrogon to treat growth hormone deficiency in pediatric patients.
Ascendis Pharma (ASND) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference
05:10pm, Monday, 24'th Jan 2022 Seeking Alpha
Ascendis' (ASND) TransCon hGH Gets EU Nod for Pediatric GHD
04:34pm, Friday, 14'th Jan 2022 Zacks Investment Research
Ascendis Pharma (ASND) gets nod in Europe for TransCon hGH for the treatment of pediatric growth hormone deficiency.
Ascendis' (ASND) TransCon hGH Gets EU Nod for Pediatric GHD
01:06pm, Friday, 14'th Jan 2022
Ascendis Pharma (ASND) gets nod in Europe for TransCon hGH for the treatment of pediatric growth hormone deficiency.
Ascendis Pharma''s Growth Hormone Deficiency Med Scores European Approval
04:44pm, Thursday, 13'th Jan 2022 Benzinga
The European Commission (EC) has granted marketing authorization to Ascendis Pharma A/S''s (NASDAQ: ASND ) Lonapegsomatropin (developed under the name TransCon hGH). The approval for TransCon covers a once-weekly subcutaneous injection for children and adolescents ages 3 to 18 years with Full story available on Benzinga.com
Ascendis Pharma''s TransCon gets EU approval for growth hormone deficiency in children
02:40pm, Thursday, 13'th Jan 2022 Seeking Alpha
Ascendis Pharma <> said the European Commission approved Lonapegsomatropin (developed under the name TransCon hGH) as a once-weekly subcutaneous injection to treat children ages 3
Ascendis Pharma's Growth Hormone Deficiency Med Scores European Approval
11:44am, Thursday, 13'th Jan 2022
The European Commission (EC) has granted marketing authorization to Ascendis Pharma A/S's (NASDAQ: ASND) Lonapegsomatropin (developed under the name TransCon hGH). The approval for TransCon covers a
Where Ascendis Pharma Stands With Analysts
03:12pm, Thursday, 06'th Jan 2022 Business Insider Markets
Analysts have provided the following ratings for Ascendis Pharma (NASDAQ: ASND ) within the last quarter:
Ascendis: Danish Biotech With Thin Audience Now Seen As Good Value By Market-Makers
05:35am, Thursday, 30'th Dec 2021
Look for surprise values in underpriced stocks. Not the story issues being ballyhooed by touts and the media - everyone knows them.
$4.34 Million in Sales Expected for Ascendis Pharma A/S (NASDAQ:ASND) This Quarter
07:26am, Friday, 24'th Dec 2021 Transcript Daily
Wall Street analysts expect that Ascendis Pharma A/S (NASDAQ:ASND) will post sales of $4.34 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Ascendis Pharma A/Ss earnings, with the highest sales estimate coming in at $9.63 million and the lowest estimate coming in at $930,000.00. Ascendis Pharma A/S []
Ascendis Pharma A/S Virtual R&D Program Update Highlights Continued Development Across R&D Pipeline
01:00pm, Tuesday, 14'th Dec 2021 Ascendis Pharma
–– TransCon™ PTH Phase 3 topline results expected in Q1 2022 and, if positive, planned NDA submission in Q3 2022 followed by expected MAA submission in Q4 2022 –– Enrollment completed in Phase 2 ACcomplisH Trial of TransCon CNP; blinded data informed dose selection of 50 and 100 μ g/kg/week in
Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of Buy from Analysts
04:44pm, Saturday, 11'th Dec 2021 Dakota Financial News
Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been assigned an average rating of Buy from the thirteen brokerages that are currently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12 month price objective among brokerages []
